A Phase 1, Open-label, Randomized, Crossover Study to Evaluate the Relative Bioavailability and Food Effect of a New Tablet Formulation of VX-993 in Healthy Adult Subjects
Latest Information Update: 15 Oct 2024
Price :
$35 *
At a glance
- Drugs VX 993 (Primary)
- Indications Pain
- Focus Pharmacokinetics
- Sponsors Vertex Pharmaceuticals
- 10 Oct 2024 Status changed from active, no longer recruiting to completed.
- 16 Sep 2024 Status changed from recruiting to active, no longer recruiting.
- 15 Aug 2024 Status changed from not yet recruiting to recruiting.